{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:23:37Z","timestamp":1787595817181,"version":"build-2736575974"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality in China. The Chinese Liver Cancer Atlas (CLCA) recently reported whole-genome sequencing of 494 HCC tumors, nominating 23 coding and 31 non-coding driver candidates based on combined\n                    <jats:italic>P<\/jats:italic>\n                    values across multiple algorithms. However, the statistical significance of recurrence alone does not distinguish functionally impactful drivers from neutral passengers. We therefore analyzed cancer effects in the CLCA dataset, quantifying the selective advantage conferred by each mutation. Whole-genome mutation calls from CLCA were analyzed. Gene- and trinucleotide context-specific neutral mutation rates were estimated for all sites. Scaled selection coefficients for every recurrent variant were quantified. Pairwise selective epistasis between genes was quantified and tested. Associations between selected driver mutations and clinical outcomes were examined in the TCGA-LIHC cohort, which included censoring information. We identified canonical drivers\n                    <jats:italic>CTNNB1<\/jats:italic>\n                    ,\n                    <jats:italic>TP53,<\/jats:italic>\n                    and the\n                    <jats:italic>TERT<\/jats:italic>\n                    -promoter hotspot as subject to intense positive selection in the CLCA cohort. We also prioritized several lower-prevalence candidate genes and variants with high inferred cancer effect sizes, including\n                    <jats:italic>P4HA1<\/jats:italic>\n                    ,\n                    <jats:italic>STAT3<\/jats:italic>\n                    , and\n                    <jats:italic>IL6ST<\/jats:italic>\n                    . These lower-prevalence events should be interpreted as computationally prioritized candidates requiring variant-level functional validation rather than as established novel HCC drivers. Conversely, some genes previously nominated as driver candidates exhibited cancer effects that were indistinguishable from neutrality. These findings show that not all recurrently mutated genes exert equivalent inferred selective effects. Such evolutionary prioritization complements recurrence based driver discovery by ranking somatic variants according to inferred selective effect, while highlighting the need for larger cohorts and functional studies to validate rare high-effect candidates.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0355717","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:27:20Z","timestamp":1787592440000},"page":"e0355717","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Driver mutation impact in Chinese hepatocellular carcinoma"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1573-5176","authenticated-orcid":true,"given":"Ruiheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houmin","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9890-3907","authenticated-orcid":true,"given":"Jeffrey P.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"issue":"4","key":"pone.0355717.ref001","first-page":"38","article-title":"Features and treatment options of Chinese hepatocellular carcinoma","volume":"2","author":"Q Wu","year":"2013","journal-title":"Chin Clin Oncol"},{"issue":"5","key":"pone.0355717.ref002","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global epidemiology and genetics of hepatocellular carcinoma","volume":"164","author":"MR Toh","year":"2023","journal-title":"Gastroenterology"},{"key":"pone.0355717.ref003","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of Hepatocellular Carcinoma","volume":"73","author":"KA McGlynn","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"pone.0355717.ref004","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2188\/jea.JE20100190","article-title":"Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures","volume":"21","author":"M Tanaka","year":"2011","journal-title":"J Epidemiol"},{"issue":"1","key":"pone.0355717.ref005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12920-024-01795-w","article-title":"Whole genome sequencing in clinical practice","volume":"17","author":"FO Bagger","year":"2024","journal-title":"BMC Med Genomics"},{"issue":"8004","key":"pone.0355717.ref006","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-024-07054-3","article-title":"Deep whole-genome analysis of 494 hepatocellular carcinomas","volume":"627","author":"L Chen","year":"2024","journal-title":"Nature"},{"issue":"3","key":"pone.0355717.ref007","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1109\/TNB.2013.2263391","article-title":"Adjusting for background mutation frequency biases improves the identification of cancer driver genes","volume":"12","author":"P Evans","year":"2013","journal-title":"IEEE Trans Nanobioscience"},{"key":"pone.0355717.ref008","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.74010","article-title":"Individualized discovery of rare cancer drivers in global network context","volume":"11","author":"I Petrov","year":"2022","journal-title":"eLife"},{"issue":"7457","key":"pone.0355717.ref009","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"MS Lawrence","year":"2013","journal-title":"Nature"},{"issue":"11","key":"pone.0355717.ref010","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/nrc3999","article-title":"The mini-driver model of polygenic cancer evolution","volume":"15","author":"F Castro-Giner","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"pone.0355717.ref011","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/0008-5472.CAN-22-1508","article-title":"Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR","volume":"83","author":"JD Mandell","year":"2023","journal-title":"Cancer Res"},{"issue":"7","key":"pone.0355717.ref012","article-title":"Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma","volume":"169","author":"Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu, Cancer Genome Atlas Research Network","year":"2017","journal-title":"Cell"},{"key":"pone.0355717.ref013","volume-title":"Modeling survival data: extending the Cox model","author":"TM Therneau","year":"2001"},{"issue":"1","key":"pone.0355717.ref014","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-018-0539-0","article-title":"MutationalPatterns: comprehensive genome-wide analysis of mutational processes","volume":"10","author":"F Blokzijl","year":"2018","journal-title":"Genome Med"},{"key":"pone.0355717.ref015","article-title":"COSMIC: the Catalogue Of Somatic Mutations In Cancer","volume":"47","author":"JG Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"pone.0355717.ref016","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.09.042","article-title":"Universal Patterns of Selection in Cancer and Somatic Tissues","volume":"171","author":"I Martincorena","year":"2017","journal-title":"Cell"},{"issue":"18","key":"pone.0355717.ref017","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1038\/s41388-017-0105-z","article-title":"Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C","volume":"37","author":"VL Cannataro","year":"2018","journal-title":"Oncogene"},{"key":"pone.0355717.ref018","doi-asserted-by":"crossref","first-page":"109091","DOI":"10.1016\/j.mbs.2023.109091","article-title":"Pairwise and higher-order epistatic effects among somatic cancer mutations across oncogenesis","volume":"366","author":"JA Alfaro-Murillo","year":"2023","journal-title":"Math Biosci"},{"issue":"2","key":"pone.0355717.ref019","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygeno.2013.04.001","article-title":"Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections","volume":"102","author":"ML Tornesello","year":"2013","journal-title":"Genomics"},{"issue":"5","key":"pone.0355717.ref020","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.18632\/oncotarget.6684","article-title":"Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma","volume":"7","author":"S Yang","year":"2016","journal-title":"Oncotarget"},{"key":"pone.0355717.ref021","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.omtn.2019.03.007","article-title":"Modulation of the IL-6-Signaling Pathway in Liver Cells by miRNAs Targeting gp130, JAK1, and\/or STAT3","volume":"16","author":"FA Servais","year":"2019","journal-title":"Molecular Therapy - Nucleic Acids"},{"issue":"7","key":"pone.0355717.ref022","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1053\/gast.2001.24798","article-title":"Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis","volume":"120","author":"P Laurent-Puig","year":"2001","journal-title":"Gastroenterology"},{"key":"pone.0355717.ref023","first-page":"697162","article-title":"Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand","volume":"2011","author":"O Galy","year":"2011","journal-title":"Hepat Res Treat"},{"key":"pone.0355717.ref024","doi-asserted-by":"crossref","first-page":"1235260","DOI":"10.3389\/fgene.2023.1235260","article-title":"Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma","volume":"14","author":"S Kumar","year":"2023","journal-title":"Front Genet"},{"issue":"4","key":"pone.0355717.ref025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"DE Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"pone.0355717.ref026","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.bbrc.2016.03.008","article-title":"MiR-30e suppresses proliferation of hepatoma cells via targeting prolyl 4-hydroxylase subunit alpha-1 (P4HA1) mRNA","volume":"472","author":"G Feng","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"pone.0355717.ref027","doi-asserted-by":"crossref","first-page":"1493420","DOI":"10.3389\/fphar.2024.1493420","article-title":"P4HA1: an important target for treating fibrosis related diseases and cancer","volume":"15","author":"X Yang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"5","key":"pone.0355717.ref028","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.01.032","article-title":"Passenger Mutations in More Than 2,500 Cancer Genomes: Overall Molecular Functional Impact and Consequences","volume":"180","author":"S Kumar","year":"2020","journal-title":"Cell"},{"key":"pone.0355717.ref029","doi-asserted-by":"crossref","first-page":"760971","DOI":"10.3389\/fonc.2021.760971","article-title":"IL-6\/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma","volume":"11","author":"J Xu","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"pone.0355717.ref030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.7150\/ijbs.97109","article-title":"Kupffer Cell-derived IL6 Promotes Hepatocellular Carcinoma Metastasis Via the JAK1-ACAP4 Pathway","volume":"21","author":"T Li","year":"2025","journal-title":"Int J Biol Sci"},{"issue":"1","key":"pone.0355717.ref031","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12672-024-01131-9","article-title":"Study of sex-biased differences in genomic profiles in East Asian hepatocellular carcinoma","volume":"15","author":"C-Y Huang","year":"2024","journal-title":"Discov Oncol"},{"issue":"7","key":"pone.0355717.ref032","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1084\/jem.20110283","article-title":"Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas","volume":"208","author":"C Pilati","year":"2011","journal-title":"J Exp Med"},{"issue":"7226","key":"pone.0355717.ref033","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nature07475","article-title":"Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours","volume":"457","author":"S Rebouissou","year":"2009","journal-title":"Nature"},{"issue":"12","key":"pone.0355717.ref034","doi-asserted-by":"crossref","DOI":"10.4161\/onci.27090","article-title":"Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma","volume":"2","author":"K Poussin","year":"2013","journal-title":"Oncoimmunology"},{"issue":"1","key":"pone.0355717.ref035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12943-017-0712-x","article-title":"The biology of Hepatocellular carcinoma: implications for genomic and immune therapies","volume":"16","author":"G Khemlina","year":"2017","journal-title":"Mol Cancer"},{"issue":"10","key":"pone.0355717.ref036","article-title":"CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma","volume":"41","author":"J-P Luo","year":"2021","journal-title":"Biosci Rep"},{"issue":"19","key":"pone.0355717.ref037","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1158\/0008-5472.CAN-08-0755","article-title":"PIK3CA Cooperates with Other Phosphatidylinositol 3\u2032-Kinase Pathway Mutations to Effect Oncogenic Transformation","volume":"68","author":"K Oda","year":"2008","journal-title":"Cancer Research"},{"issue":"10","key":"pone.0355717.ref038","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.18632\/oncotarget.1687","article-title":"Identification of novel therapeutic targets in the PI3K\/AKT\/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing","volume":"5","author":"F Janku","year":"2014","journal-title":"Oncotarget"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0355717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:27:27Z","timestamp":1787592447000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0355717"}},"subtitle":[],"editor":[{"given":"Alexis G. Murillo","family":"Carrasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0355717","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}